Moderna (NASDAQ:MRNA) Stock Price Expected to Rise, Berenberg Bank Analyst Says

Moderna (NASDAQ:MRNA) had its price target raised by equities research analysts at Berenberg Bank from $33.00 to $42.00 in a research report issued to clients and investors on Thursday. The firm presently has a “hold” rating on the stock. Berenberg Bank’s price objective would indicate a potential upside of 24.46% from the company’s current price.

Several other research firms also recently issued reports on MRNA. Wolfe Research assumed coverage on shares of Moderna in a research note on Friday, November 15th. They set an “underperform” rating and a $40.00 price objective for the company. Royal Bank of Canada reiterated a “sector perform” rating and issued a $75.00 price target on shares of Moderna in a report on Thursday, September 19th. Jefferies Financial Group decreased their target price on Moderna from $65.00 to $55.00 and set a “hold” rating for the company in a research report on Tuesday, October 15th. Barclays dropped their target price on Moderna from $125.00 to $111.00 and set an “overweight” rating on the stock in a report on Friday, November 8th. Finally, Sanford C. Bernstein started coverage on shares of Moderna in a research report on Thursday, October 17th. They issued a “market perform” rating and a $55.00 price objective for the company. Four research analysts have rated the stock with a sell rating, thirteen have given a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Moderna has a consensus rating of “Hold” and a consensus target price of $75.58.

Moderna Trading Down 2.9 %

MRNA traded down $1.02 during midday trading on Thursday, hitting $33.75. The company’s stock had a trading volume of 6,240,972 shares, compared to its average volume of 12,270,938. Moderna has a 52-week low of $31.94 and a 52-week high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The firm has a 50-day moving average price of $41.44 and a two-hundred day moving average price of $67.56. The firm has a market cap of $12.99 billion, a P/E ratio of -5.80 and a beta of 1.60.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Thursday, November 7th. The company reported $0.03 EPS for the quarter, topping the consensus estimate of ($1.89) by $1.92. The company had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative return on equity of 17.68% and a negative net margin of 43.77%. The firm’s revenue was up 3.8% on a year-over-year basis. During the same period in the prior year, the firm posted ($1.39) earnings per share. On average, research analysts anticipate that Moderna will post -9.3 earnings per share for the current year.

Insider Activity

In related news, insider Shannon Thyme Klinger sold 1,418 shares of the firm’s stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $42.79, for a total value of $60,676.22. Following the completion of the transaction, the insider now owns 19,717 shares of the company’s stock, valued at approximately $843,690.43. This trade represents a 6.71 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders sold a total of 2,664 shares of company stock valued at $115,210 over the last three months. Insiders own 15.20% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of MRNA. Axiom Advisory LLC grew its position in Moderna by 1.6% during the third quarter. Axiom Advisory LLC now owns 12,672 shares of the company’s stock valued at $847,000 after purchasing an additional 198 shares in the last quarter. Arkadios Wealth Advisors increased its stake in shares of Moderna by 2.2% during the 3rd quarter. Arkadios Wealth Advisors now owns 11,429 shares of the company’s stock worth $764,000 after purchasing an additional 243 shares during the last quarter. Knuff & Co LLC boosted its stake in shares of Moderna by 5.4% during the 3rd quarter. Knuff & Co LLC now owns 4,732 shares of the company’s stock worth $316,000 after acquiring an additional 244 shares in the last quarter. Stephens Inc. AR raised its position in shares of Moderna by 7.9% in the third quarter. Stephens Inc. AR now owns 3,334 shares of the company’s stock valued at $223,000 after purchasing an additional 245 shares during the period. Finally, Mather Group LLC. lifted its position in Moderna by 25.7% during the 3rd quarter. Mather Group LLC. now owns 1,281 shares of the company’s stock worth $86,000 after acquiring an additional 262 shares during the last quarter. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.